Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

Heat shock protein (HSP)90 inhibitors have shown significant anti-tumor activities in preclinical settings in both solid and hematological tumors. We previously reported that the novel, orally available HSP90α/β inhibitor TAS-116 shows significant anti-MM activities. In this study, we further examin...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:PLoS One
Main Authors: Suzuki, Rikio, Kikuchi, Shohei, Harada, Takeshi, Mimura, Naoya, Minami, Jiro, Ohguchi, Hiroto, Yoshida, Yasuhiro, Sagawa, Morihiko, Gorgun, Gullu, Cirstea, Diana, Cottini, Francesca, Jakubikova, Jana, Tai, Yu-Tzu, Chauhan, Dharminder, Richardson, Paul G., Munshi, Nikhil, Ando, Kiyoshi, Utsugi, Teruhiro, Hideshima, Teru, Anderson, Kenneth C.
פורמט: Artigo
שפה:Inglês
יצא לאור: Public Library of Science 2015
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4667922/
https://ncbi.nlm.nih.gov/pubmed/26630652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0143847
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים